Role of vinca alkaloids and their derivatives in cancer therapy
1 Sanskar College of Pharmacy and Research (SCPR), Opp. Jindal Pipes ltd, NH-24, Jindal Nagar, Ghaziabad, Uttar Pradesh 201302, India.
2 Sunder Deep Pharmacy College (SDPC), NH-24, Delhi-Hapur Road, Dasna, Ghaziabad, Uttar Pradesh 201015, India.
Review Article
World Journal of Advanced Research and Reviews, 2022, 16(03), 794-800
Article DOI: 10.30574/wjarr.2022.16.3.1378
Publication history:
Received on 06 November 2022; revised on 20 December 2022; accepted on 23 December 2022
Abstract:
Vinca alkaloids and its derivatives like Vincristine, Vinblastine etc. isolated from Catharanthus roseus plants are widely used in the treatment of various types of cancers. Mode of action of Vinca alkaloids (vinblastine, vincristine, vinorelbine) is microtubule-stabilizing agents (MTAs) i.e., arrest the cell cycle via disrupting microtubule dynamics. Vincristine major side effect is neurotoxicity. Hoverer, Vincristine induce neuropathy in mice or rat, used as animal model to study effect of drugs or plants by various authors also reported in review literature. Vinca alkaloids and its derivatives were widely used drugs in combination regimens with cyclophosphamide, doxorubicin, procarbazine, Methotrexate and dacarbazine etc. in various types of cancer. In this review, we also discussed major structure modifications position of chemically synthesized vincristine and vinblastine derivatives required for potential anticancer activities. Anticancer mechanism and some major patents on vinca alkaloids derivatives also reported in this review article. The study of Vinca alkaloids and its derivatives a class of an antimitotic compounds, found essential role in anticancer therapies.
Keywords:
Cancer; Vinca Alkaloids; Microtubule-stabilizing agents (MTAs); Vincristine (VCR) induce neuropathy
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0